Expression of CTB-10×rolGLP-1 in E.coli and Its Therapeutic Effect on Type 2 Diabetes

E-ISSN： 1873-4316|16|6|564-572

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.16, Iss.6, 2015-06, pp. : 564-572

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expression and Purification of Optimized rolGLP-1, A Novel GLP-1 Analog, in Escherichia Coli BL21(DE3) and its Good Glucoregulatory Effect on Type 2 Diabetic Mice

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 11, 2013-11 ,pp. : 985-994

Bentham Science Publishers

Access to resources Recommend Favorite

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations

By Jespersen Maria J Knop Filip K Christensen Mikkel

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 17-29

Informa Healthcare

Access to resources Recommend Favorite

GLP-1 agonists: a new approach for type 2 diabetes

Inpharma, Vol. 1, Iss. 1407, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Continuous GLP-1 (7-36) amide effective in type 2 diabetes

Inpharma, Vol. 1, Iss. 1329, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

GLP-1 7-36 amide: potential in type 2 diabetes

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite